The U.S. stock market delivered another powerful performance in 2025, driven largely by artificial intelligence spending, resilient consumer demand, and steady corporate earnings growth. The challenge for investors heading into 2026 is no longer finding stocks that went up, but identifying which of those winners still offer attractive valuations after the rally.
Two companies stand out for combining strong year to date gains with modest forward price to earnings ratios and broad analyst support. CVS Health and Micron Technology both significantly outperformed the broader market in 2025 while still trading at valuation levels that suggest further upside potential if earnings projections hold.
Strong Market Backdrop Raises the Bar for Value
The overall market set a high standard this year. The tech heavy Nasdaq Composite surged more than 20 percent as investors poured capital into semiconductor, cloud computing, and automation stocks. The broader S&P 500 advanced close to 16 percent, while the Dow Jones Industrial Average rose roughly 11.5 percent.
Against that backdrop, only a limited group of stocks managed to beat the market while remaining inexpensive on a forward earnings basis. CVS Health and Micron Technology are among the most compelling examples of that rare combination.
CVS Health: A Turnaround Story Still Priced for Caution
Shares of CVS Health surged more than 70 percent in 2025 as the company delivered stronger than expected earnings and made visible progress stabilizing its insurance and pharmacy operations. Despite the sharp rally, the stock still trades at roughly 11 times forward earnings, placing it well below the market average.
CVS benefited from improving performance at its Aetna insurance unit and higher profitability across its retail pharmacy business. In late October, the company reported quarterly earnings and revenue that exceeded analyst expectations and raised its adjusted profit outlook for the year.
At the same time, management took a cautious tone regarding part of its long term growth outlook. The company warned that it expects “modestly lower growth” in its Caremark pharmacy benefit manager business as pricing contracts reset over the next several years. That conservative guidance likely helped keep the stock from becoming overly expensive despite its strong rebound.
Wall Street analysts remain broadly optimistic. Consensus price targets still imply double digit percentage upside from recent trading levels. CVS also continues to pay a dividend, which adds to its appeal for income focused investors seeking stability alongside growth heading into 2026.
From a strategic perspective, CVS sits at the center of several durable trends including rising prescription demand, an aging population, and continued cost pressures across the health care system that favor scale providers with nationwide reach.
Micron Technology: AI-Driven Growth With a Low Multiple
Micron Technology delivered one of the most dramatic rallies of the year, soaring well over 100 percent as demand for memory chips surged alongside global investment in artificial intelligence infrastructure. Even after that massive run, Micron still trades at a forward price to earnings ratio near 12.
The company is benefiting from tight supply conditions in key memory products including DRAM, which is a core component of data center servers, AI accelerators, and consumer electronics. Limited capacity additions across the industry have given Micron increased pricing power at the same time demand continues to rise.
Analysts remain firmly bullish. One of the most optimistic outlooks came from Morgan Stanley analyst Joseph Moore, who recently reiterated an overweight rating on the stock and labeled it a top pick. He said that ongoing shortages in dynamic random access memory should significantly lift the company’s long term earnings potential. Moore wrote, “We believe that’s going to move us firmly into uncharted territory from an earnings standpoint, and we think the stock has yet to fully price in the upside that’s coming.”
That view reflects a broader belief across Wall Street that Micron is entering the early stages of a multi year earnings expansion fueled by artificial intelligence, cloud computing, and data center growth.
Micron also carries additional optionality tied to geopolitical efforts to diversify semiconductor supply chains away from concentrated manufacturing regions, which could support long term capital investment and government incentives.
Why These Two Stocks Still Matter Heading Into 2026
Investors often assume that once a stock posts triple digit percentage gains, the upside is gone. History shows that is not always the case, especially when earnings growth accelerates faster than share prices. Both CVS Health and Micron Technology are examples of companies where fundamentals have improved rapidly while valuations remain restrained.
Several macro factors support continued investor interest in both names:
• Higher interest rates favor companies with real earnings and strong cash flow
• Health care spending remains resilient even during economic slowdowns
• Artificial intelligence infrastructure spending continues to expand globally
• Tight capital discipline across industries is supporting pricing power
These forces create a favorable environment for stocks that can deliver earnings growth without relying solely on multiple expansion.
Investor Takeaway
CVS Health and Micron Technology have already proven they can outperform the market. What makes them unique heading into 2026 is that they still trade at valuation levels typically associated with much slower growing companies.
For investors looking to balance momentum with discipline, both stocks offer exposure to powerful long term trends while maintaining downside support through earnings strength and reasonable forward multiples.
If the current earnings trajectories hold, both companies may still have meaningful room to run even after their blockbuster performances in 2025.
About Author
